Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

被引:0
|
作者
Hamamah, Sevag [1 ]
Iatcu, Oana C. [2 ]
Covasa, Mihai [2 ]
机构
[1] Scripps Mercy Hosp, Dept Internal Med, San Diego, CA 92103 USA
[2] Univ Suceava, Coll Med & Biol Sci, Dept Biomed Sci, Suceava 720229, Romania
关键词
liver disease; gut bacteria; Western diet; Mediterranean diet; ketogenic diet; intermittent fasting; FATTY LIVER; PPAR-GAMMA; MEDITERRANEAN DIET; HEPATIC STEATOSIS; NONALCOHOLIC STEATOHEPATITIS; SYNERGISTIC INTERACTION; INTESTINAL MICROBIOTA; ENERGY-EXPENDITURE; LIPID-METABOLISM; EGG CONSUMPTION;
D O I
10.3390/nu17010143
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major contributor to liver-related morbidity, cardiovascular disease, and metabolic complications. Lifestyle interventions, including diet and exercise, are first line in treating MASLD. Dietary approaches such as the low-glycemic-index Mediterranean diet, the ketogenic diet, intermittent fasting, and high fiber diets have demonstrated potential in addressing the metabolic dysfunction underlying this condition. The development and progression of MASLD are closely associated with taxonomic shifts in gut microbial communities, a relationship well-documented in the literature. Given the importance of diet as a primary treatment for MASLD, it is important to understand how gut microbiota and their metabolic byproducts mediate favorable outcomes induced by healthy dietary patterns. Conversely, microbiota changes conferred by unhealthy dietary patterns such as the Western diet may induce dysbiosis and influence steatotic liver disease through promoting hepatic inflammation, up-regulating lipogenesis, dysregulating bile acid metabolism, increasing insulin resistance, and causing oxidative damage in hepatocytes. Although emerging evidence has identified links between diet, microbiota, and development of MASLD, significant gaps remain in understanding specific microbial roles, metabolite pathways, host interactions, and causal relationships. Therefore, this review aims to provide mechanistic insights into the role of microbiota-mediated processes through the analysis of both healthy and unhealthy dietary patterns and their contribution to MASLD pathophysiology. By better elucidating the interplay between dietary nutrients, microbiota-mediated processes, and the onset and progression of steatotic liver disease, this work aims to identify new opportunities for targeted dietary interventions to treat MASLD efficiently.
引用
收藏
页数:43
相关论文
共 50 条
  • [21] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255
  • [22] The gut-liver axis and metabolic dysfunction-associated steatotic liver disease
    Demir, Muenevver
    Tacke, Frank
    Mueller-Schilling, Martina
    Schmid, Stephan
    GASTROENTEROLOGIE, 2025,
  • [23] Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
    Chan, Wah-Kheong
    Chuah, Kee-Huat
    Rajaram, Ruveena Bhavani
    Lim, Lee-Ling
    Ratnasingam, Jeyakantha
    Vethakkan, Shireene Ratna
    JOURNAL OF OBESITY & METABOLIC SYNDROME, 2023, 32 (03) : 197 - 213
  • [24] EATING DISORDERS IN MEXICAN POPULATION WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Contreras, Ana D. Cano
    Alvarez, Hector Ricardo Ordaz
    Priego-Parra, Bryan Adrian
    Martinez-Perez, Genesis Patricia
    Reyes-Diaz, Sara A.
    Azamar, Pamela Duran
    Garcia-Carvajal, Mario J.
    Diaz-Crespo, Angel H.
    Vazquez-Cruz, Anette P.
    Hernandez, Tonatiu Castellanos
    Basurto, Jose Luis Vargas
    Dietlen, Federico B. Roesch
    Francisco, Maria D.
    Amieva-Balmori, Mercedes
    Remes-Troche, Jose Maria
    GASTROENTEROLOGY, 2024, 166 (05) : S1649 - S1650
  • [25] Evaluation of a Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Clinical Pharmacy Service
    Sallam, Sandy
    Ahmed, Aijaz
    Gu, Xin
    DIABETES, 2024, 73
  • [26] Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
    Nakamura, Toru
    Masuda, Atsutaka
    Nakano, Dan
    Amano, Keisuke
    Sano, Tomoya
    Nakano, Masahito
    Kawaguchi, Takumi
    CELLS, 2025, 14 (06)
  • [27] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [28] Gout drives metabolic dysfunction-associated steatotic liver disease through gut microbiota and inflammatory mediators
    Liu, Siyuan
    Li, Fan
    Cai, Yunjia
    Sun, Lin
    Ren, Linan
    Yin, Mengsha
    Cui, Huijuan
    Pan, Yujie
    Gang, Xiaokun
    Wang, Guixia
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [29] Gut microbiota-NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease
    Yu, Tingting
    Luo, Lei
    Xue, Juan
    Tang, Wenqian
    Wu, Xiaojie
    Yang, Fan
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (08)
  • [30] THE PROGNOSTIC ROLE OF THE ELF TEST, COMPARED TO LIVER BIOPSY, IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Liguori, A.
    D'Ambrosio, F.
    Nicholas, V.
    Termite, F.
    Petrucci, L.
    Beschi, R.
    Orienti, M.
    Galletti, S.
    Cardinali, S.
    Riccardi, L.
    Pizzolante, F.
    De, Matthaeis N.
    Zocco, M. A.
    Giustiniani, M. C.
    Marrone, G.
    Biolato, M.
    Cefalo, C.
    Vecchio, F. M.
    Pompili, M.
    Rapaccini, G. L.
    Grieco, A.
    Urbani, A.
    Sanguinetti, M.
    Gasbarrini, A.
    Miele, L.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S257 - S257